DOCSLIB.ORG

Laws and Regulations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laws and Regulations E/NL.2005/32-37 7 September 2005 UNITED NATIONS English only LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES In accordance with the relevant articles of the international treaties on narcotic drugs and psychotropic substances, the Secretary-General has the honour to communicate the following legislative text / texts UNITED KINGDOM AND NORTHERN IRELAND Communicated by the Government of United Kingdom and Northern Ireland NOTE BY THE SECRETARIAT (a) Some editing of texts may be done by the Secretariat in the interest of clarity. In this connection, words in square brackets [ ] have been added or changed by the Secretariat. (b) Only passages directly relevant to the control of narcotic drugs or psychotropic substances have been reproduced in this document. Non-relevant parts of laws and regulations have been deleted by the Secretariat; such deletions are indicated by [...]. CONTENTS PAGE E/NL.2005/32 Statutory Instruments 2001 Nº 3932: Dangerous Drugs, The Misuse of Drugs Act 1971 (Modification) Order 2001 E/NL.2005/33 Statutory Instruments 2001 Nº 3998: Dangerous Drugs, The Misuse of Drugs Regulations 2001 E/NL.2005/34 Statutory Instruments 2001 Nº 3997: Dangerous Drugs, The Misuse of Drugs (Designation) Order 2001 E/NL.2005/35 Statuary Instruments 2003 Nº 1432: Dangerous Drugs, The Misuse of Drugs (Amendment) Regulations 2003 E/NL.2005/36 Statuary Instruments 2003 Nº 1653: Dangerous Drugs, The Misuse of Drugs (Amendment) (Nº 2) Regulations 2003 E/NL.2005/37 Statuary Instruments 2003 Nº 3201: Dangerous Drugs, The Misuse of Drugs Act 1971 (Modification) (Nº 2) Order 2003 V.05-88045 (E) *0588045* E/NL.2005/32-37 Page 2 E/NL.2005/32 STATUTORY INSTRUMENTS 2001 Nº 3932 DANGEROUS DRUGS THE MISUSE OF DRUGS ACT 1971 (MODIFICATION) ORDER 2001 Date of Adoption: 13 December 2001 Date of Entry into Force: 1 February 2002 At the Court at Buckingham Palace, the 11th day of December 2001 Present, The Queen's Most Excellent Majesty in Council Whereas a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and has been approved by a resolution of each House of Parliament: 1 Now, therefore, Her Majesty, in pursuance of section 2(2) of the Misuse of Drugs Act 1971[1] , is pleased, by and with the advice of Her Privy Council, to order, and it is hereby ordered, as follows: 1.This Order may be cited as the Misuse of Drugs Act 1971 (Modification) Order 2001 and shall come into force on 1st February 2002. 2. - (1) Schedule 2 to the Misuse of Drugs Act 1971 [2] (which specifies the drugs which are subject to control under that Act) shall be amended as follows. (2) After sub-paragraph (b) of paragraph 1 of Part I of that Schedule there shall be inserted the following sub- paragraph - "(ba) the following phenethylamine derivatives, namely: - Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol 2-Amino-1-(3,4-dimethoxyphenyl)ethanol Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine 4-Bromo-ß,2,5-trimethoxyphenethylamine N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine Cyclopropylmethyl(α-methyl-3,4-methylenedioxyphenethyl)amine 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine 2-(1,4-Dimethoxy-2-naphthyl)ethylamine 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine α,α-Dimethyl-3,4-methylenedioxyphenethylamine α,α-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine 4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine 2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine 1 Note by the Secretariat: E/NL.1971/42 E/NL.2005/32-37 Page 3 ß-Methoxy-3,4-methylenedioxyphenethylamine U 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine 2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine α-Methyl-4-(methylthio)phenethylamine ß,3,4,5-Tetramethoxyphenethylamine ß,2,5-Trimethoxy-4-methylphenethylamine;". (3) In paragraph 1(a) of Part II of that Schedule after the word "Methylamphetamine" there shall be inserted the word "α-Methylphenethylhydroxylamine;". A. K. Galloway Clerk of the Privy Council 2 Notes: 2 Original Notes: [1] 1971 c. 38. [2] Schedule 2 has been amended by S.I. 1973/771, 1975/421, 1977/1243, 1979/299, 1983/765, 1984/859, 1985/1995, 1986/2230, 1989/1340, 1990/2589, 1995/1966, 1996/1300 and 1998/750. E/NL.2005/32-37 Page 4 E//NL.2005/33 STATUTORY INSTRUMENTS 2001 Nº 3998 DANGEROUS DRUGS THE MISUSE OF DRUGS REGULATIONS 2001 Date of Adoption: 13 December 2001 Date of Entry into Force: 1 February 2002 ARRANGEMENT OF REGULATIONS 1. Citation and commencement. 2. Interpretation. 3. Specification of controlled drugs for purposes of Regulations. 4. Exceptions for drugs in Schedules 4 and 5 and poppy-straw. 5. Licences to produce etc. controlled drugs. 6. General authority to supply and possess. 7. Administration of drugs in Schedules 2, 3, 4 and 5. 8. Production and supply of drugs in Schedules 2 and 5. 9. Production and supply of drugs in Schedules 3 and 4. 10. Possession of drugs in Schedules 2, 3 and 4. 11. Exemption for midwives. 12. Cultivation under licence of cannabis plant. 13. Approval of premises for cannabis smoking for research purposes. 14. Documents to be obtained by supplier of controlled drugs. 15. Form of prescriptions. 16. Provisions as to supply on prescription. 17. Exemption for certain prescriptions. 18. Marking of bottles and other containers. 19. Record-keeping requirements in respect of drugs in Schedules 1 and 2. 20. Requirements as to registers. 21. Record-keeping requirements in respect of drugs in Schedule 2 in particular cases. 22. Record-keeping requirements in respect of drugs in Schedules 3 and 4. 23. Preservation of registers, books and other documents. 24. Preservation of records relating to drugs in Schedules 3 and 5. 25. Exempt products. 26. Furnishing of information with respect to controlled drugs. 27. Destruction of controlled drugs. 28. Revocations. E/NL.2005/32-37 Page 5 SCHEDULES Schedule 1 Controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27. Schedule 2 Controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27. Schedule 3 Controlled drugs subject to the requirements of regulations 14, 15 (except temazepam), 16, 18, 22, 23, 24, 26 and 27. Schedule 4 Part I Controlled drugs subject to the requirements of regulations 22, 23, 26 and 27. Part II Controlled drugs excepted from the prohibition on possession when in the form of a medicinal product; excluded from the application of offences arising from the prohibition on importation and exportation when imported or exported in the form of a medicinal product by any person for administration to himself; and subject to the requirements of regulations 22, 23, 26 and 27. Schedule 5 Controlled drugs excepted from the prohibition on importation, exportation and possession and subject to the requirements of regulations 24 and 26. Schedule 6 Form of register. Schedule 7 Regulations revoked. The Secretary of State, in exercise of the powers conferred on him by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971[1], after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 31(3) of that Act, hereby makes the following Regulations: Citation and commencement 1.These Regulations may be cited as the Misuse of Drugs Regulations 2001 and shall come into force on 1st February 2002. Interpretation 2. - (1) In these Regulations, unless the context otherwise requires - 2 "the Act" means the Misuse of Drugs Act 1971; "authorised as a member of a group" means authorised by virtue of being a member of a class as respects which the Secretary of State has granted an authority under and for the purposes of regulation 8(3), 9(3) or 10(3) which is in force, and "his group authority", in relation to a person who is a member of such a class, means the authority so granted to that class; "document" has the same meaning as in Part I of the Civil Evidence Act 1968[2]; "exempt product" means a preparation or other product consisting of one or more component parts, any of which contains a controlled drug, where - (a) the preparation or other product is not designed for administration of the controlled drug to a human being or animal; (b) the controlled drug in any component part is packaged in such a form, or in combination with other active or inert substances in such a manner, that it cannot be recovered by readily applicable means or in a yield which constitutes a risk to health; and (c) no one component part of the product or preparation contains more than one
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • 159 Misuse of Drugs (Controlled Drugs) Order 2001
    MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 BR 37/2001 MISUSE OF DRUGS ACT 1972 1972 : 159 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 The Minister of Health and Family Services, in exercise of the powers conferred on him by section 3(2) of the Misuse Of Drugs Act 1972, makes the following Order: Citation 1 This Order may be cited as the Misuse Of Drugs (Controlled Drugs) Order 2001. Amendment of Schedule 2 to Act No. 159 of 1972 2 Part I of Schedule 2 to the Misuse of Drugs Act 1972 is deleted and the new Part I set forth in the Schedule to this Order is substituted. Commencement 3 This Order commences on 1st August, 2001. SCHEDULE 2 (paragraph 2) PART I 1. The following substances and products, namely:- (a) ACETORPHINE ACETYLDIHYDROCODEINE ALFENTANIL ALLYLPRODINE ALPHACETYLMETHADOL 1989 Revision 1 MISUSE OF DRUGS (CONTROLLED DRUGS) ORDER 2001 ALPHAMEPRODINE ALPHAMETHADOL ALPHAPRODINE ALPRAZOLAM AMPHETAMINE ANILERIDINE ATAMESTANE BENZETHIDINE BENZPHETAMINE BENZYLMORPHINE (3-Benzylmorphine) BETACETYLMETHADOL BETAMEPRODINE BETAMETHADOL BETAPRODINE BEZITRAMIDE BOLANDIOL BOLASTERONE BOLAZINE BOLDENONE BOLENOL BOLMANTALATE BROMAZEPAM BUFOTENINE BUPRENORPHINE CALUUSTERONE CAMAZEPAM CANNABINOL DERIVATIVES CANNABINOL except where contained in Cannabis or Cannabis resin CANNABIS AND CANNABIS RESIN CARFENTANIL CATHINE CATHINONE CHLORDIAZEPOXIDE CHLORPHENTERMINE 4-CHLOROMETHANDIENONE CHORIONIC GONADOTROPHIN (HCG) and NON-HUMAN CHORIONIC GONADOTROPHIN CLENBUTEROL CLOBAZAM CLONAZEPAM CLONITAZENE CLORAZEPIC ACID CLOSTEBOL 2 1989 Revision MISUSE
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 April 2020 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 April 2020 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • Pound. Mepitiostane Administered Orally Suppressed the Growth of Transplanted Estrogen-Dependent Mammary Tumor in Rats
    NOTE [Gann, 68, 337～341; June, 1977] INHIBITORY EFFECT OF MEPITIOSTANE ON THE GROWTH OF MAMMARY TUMOR OF A RAT Osamu TAKATANI and Soichi KUMAOKA National Cancer Center Hospital* Mepitiostane (2α, 3α-epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether) is an orally active anti-estrogenic and anabolic-androgenic steroid com- pound. Mepitiostane administered orally suppressed the growth of transplanted estrogen-dependent mammary tumor in rats. This result was compared with the oral administration of fluoxymesterone, which is widely used orally for treatment of advanced breast cancer. Experimental result showed that Me- pitiostane has a more dominant antitumor activity than fluoxymesterone. There- fore, this new compound may be useful for clinical treatment of breast cancer. In 1965, Takeda and his colleagues10) syn- thesized 2α, 3α-epithio-5α-androstan-17β-ol (epitiostanol) and its biological activities were reported by Miyake et al.5,6) Takatani9) had studied its antitumor activity by using mam- mary tumors of rats and mice. Miyake7,8) reported that a derivative of epitiostanol, 2α, 3α-epithio-5α-androstan-17β-yl 1-metho- xycyclopentyl ether (Mepitiostane) was a new and orally active anti-estrogenic and anabolic-androgenic steroid compound. It does not possess the characteristic alkyl struc- ture at 17α-position (Fig. 1). In this paper, the effect of Mepitiostane on the growth of transplanted estrogen-de- pendent mammary tumor in rats is reported as a second study of sequential studies on epitiostanol.9) Materials and Methods Mammary fibroadenoma from a female rat of the Sprague-Dawley strain was supplied by Dr . R. Fukunishi, Department of Pathology , Ehime University Medical School.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]